These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 23043368

  • 1. Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study.
    van Hartingsveldt B, Nnane IP, Bouman-Thio E, Loza MJ, Piantone A, Davis HM, Petty KJ.
    Br J Clin Pharmacol; 2013 May; 75(5):1289-98. PubMed ID: 23043368
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study.
    Xu Z, Bouman-Thio E, Comisar C, Frederick B, Van Hartingsveldt B, Marini JC, Davis HM, Zhou H.
    Br J Clin Pharmacol; 2011 Aug; 72(2):270-81. PubMed ID: 21392075
    [Abstract] [Full Text] [Related]

  • 3. The first-in-human study of CNTO 7160, an anti-interleukin-33 receptor monoclonal antibody, in healthy subjects and patients with asthma or atopic dermatitis.
    Nnane I, Frederick B, Yao Z, Raible D, Shu C, Badorrek P, van den Boer M, Branigan P, Duffy K, Baribaud F, Fink D, Yang TY, Xu Z.
    Br J Clin Pharmacol; 2020 Dec; 86(12):2507-2518. PubMed ID: 32415720
    [Abstract] [Full Text] [Related]

  • 4. A phase I, single and fractionated, ascending-dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietin mimetic antibody fusion protein (CNTO 528) in healthy male subjects.
    Bouman-Thio E, Franson K, Miller B, Getsy J, Cohen A, Bai SA, Yohrling J, Frederick B, Marciniak S, Jiao Q, Jang H, Davis H, Burggraaf J.
    J Clin Pharmacol; 2008 Oct; 48(10):1197-207. PubMed ID: 18812609
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Stapokibart in Healthy Volunteers and Adult Subjects with Atopic Dermatitis.
    Zhang L, Zhang W, Xu Y, Dong L, Sun Y, Jia Y, Li Z, Chen B, Hou J, Zhang J.
    Adv Ther; 2024 Jul; 41(7):2953-2965. PubMed ID: 38833140
    [Abstract] [Full Text] [Related]

  • 6. A Double-Blind, Phase I, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BOS161721 in Healthy Subjects.
    Hussaini A, Mukherjee R, Berdieva DM, Glogowski C, Mountfield R, Ho PTC.
    Clin Transl Sci; 2020 Mar; 13(2):337-344. PubMed ID: 31664766
    [Abstract] [Full Text] [Related]

  • 7. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.
    Schiopu E, Chatterjee S, Hsu V, Flor A, Cimbora D, Patra K, Yao W, Li J, Streicher K, McKeever K, White B, Katz E, Drappa J, Sweeny S, Herbst R.
    Arthritis Res Ther; 2016 Jun 07; 18(1):131. PubMed ID: 27267753
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics and safety of sirukumab following a single subcutaneous administration to healthy Japanese and Caucasian subjects.
    Zhuang Y, Xu Z, de Vries DE, Wang Q, Shishido A, Comisar C, Ford JA, Keen M, Achira M, Tsukamoto Y, Petty KJ, Davis HM, Zhou H.
    Int J Clin Pharmacol Ther; 2013 Mar 07; 51(3):187-99. PubMed ID: 23357841
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics and pharmacodynamics of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, following single-dose administration by subcutaneous and intravenous routes to healthy subjects.
    Zhang X, Georgy A, Rowell L.
    Int J Clin Pharmacol Ther; 2013 Jun 07; 51(6):443-55. PubMed ID: 23547848
    [Abstract] [Full Text] [Related]

  • 10. Safety, Tolerability, and Pharmacokinetics of PF-06823859, an Anti-Interferon β Monoclonal Antibody: A Randomized, Phase I, Single- and Multiple-Ascending-Dose Study.
    Neelakantan S, Oemar B, Johnson K, Rath N, Salganik M, Berman G, Pelletier K, Cox L, Page K, Messing D, Tarabar S.
    Clin Pharmacol Drug Dev; 2021 Mar 07; 10(3):307-316. PubMed ID: 33352008
    [Abstract] [Full Text] [Related]

  • 11. Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Anti-IFNAR1 Monoclonal Antibody QX006N: A First-in-Human Single Ascending Dose Study in Healthy Chinese Volunteers.
    Li X, Li B, Wang M, Fang M, Lou J, Liu J, Chen H, Ding Y.
    BioDrugs; 2024 Mar 07; 38(2):313-321. PubMed ID: 38148466
    [Abstract] [Full Text] [Related]

  • 12. Modification of the Fc Region of a Human Anti-oncostatin M Monoclonal Antibody for Higher Affinity to FcRn Receptor and Extension of Half-life in Cynomolgus Monkeys.
    Nnane IP, Han C, Jiao Q, Tam SH, Davis HM, Xu Z.
    Basic Clin Pharmacol Toxicol; 2017 Jul 07; 121(1):13-21. PubMed ID: 28132416
    [Abstract] [Full Text] [Related]

  • 13. Non-Clinical Pharmacokinetics, Prediction of Human Pharmacokinetics and First-in-Human Dose Selection for CNTO 5825, an Anti-Interleukin-13 Monoclonal Antibody.
    Nnane IP, Xu Z, Zhou H, Davis HM.
    Basic Clin Pharmacol Toxicol; 2015 Oct 07; 117(4):219-25. PubMed ID: 25683750
    [Abstract] [Full Text] [Related]

  • 14. Clinical pharmacology of AMG 181, a gut-specific human anti-α4β7 monoclonal antibody, for treating inflammatory bowel diseases.
    Pan WJ, Köck K, Rees WA, Sullivan BA, Evangelista CM, Yen M, Andrews JM, Radford-Smith GL, Prince PJ, Reynhardt KO, Doherty DR, Patel SK, Krill CD, Zhou K, Shen J, Smith LE, Gow JM, Lee J, Treacy AM, Yu Z, Platt VM, Borie DC.
    Br J Clin Pharmacol; 2014 Dec 07; 78(6):1315-33. PubMed ID: 24803302
    [Abstract] [Full Text] [Related]

  • 15. Safety, tolerability, pharmacokinetics and pharmacodynamics of a single intravenous dose of SHR-1707 in healthy adult subjects: two randomized, double-blind, single-ascending-dose, phase 1 studies.
    Yang Y, Qiu H, Fan Y, Zhang Q, Qin H, Wu J, Zhang X, Liu Y, Zhou R, Zhang Q, Ye Z, Ma J, Xu Y, Feng S, Fei Y, Li N, Cui X, Dong F, Wang Q, Shen K, Shakib S, Williams J, Hu W.
    Alzheimers Res Ther; 2024 Oct 10; 16(1):218. PubMed ID: 39390616
    [Abstract] [Full Text] [Related]

  • 16. First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis.
    Zhuang Y, Calderon C, Marciniak SJ, Bouman-Thio E, Szapary P, Yang TY, Schantz A, Davis HM, Zhou H, Xu Z.
    Eur J Clin Pharmacol; 2016 Nov 10; 72(11):1303-1310. PubMed ID: 27515978
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics of Tildrakizumab (MK-3222), an Anti-IL-23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy Subjects.
    Khalilieh S, Hodsman P, Xu C, Tzontcheva A, Glasgow S, Montgomery D.
    Basic Clin Pharmacol Toxicol; 2018 Sep 10; 123(3):294-300. PubMed ID: 29510001
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Anti-IL21 receptor monoclonal antibody (ATR-107): Safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study.
    Hua F, Comer GM, Stockert L, Jin B, Nowak J, Pleasic-Williams S, Wunderlich D, Cheng J, Beebe JS.
    J Clin Pharmacol; 2014 Jan 10; 54(1):14-22. PubMed ID: 23913720
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.